Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520899 | 1.00 | HSD11B1 (0.43) | HSD11B1CCR2NTRK3SRPK1MAOB | |
| SCHEMBL4257843 | 1.00 | HSD11B1 (0.43) | HSD11B1CCR2NTRK3SRPK1MAOB | |
| SCHEMBL11077137 | 0.83 | MAOB (0.46) | HSD11B1MAOBHTR2CLMNAHTT | |
| SCHEMBL11079999 | 0.83 | MAOB (0.46) | HSD11B1MAOBHTR2CLMNAHTT | |
| SCHEMBL10651717 | 0.83 | MAOB (0.46) | HSD11B1MAOBHTR2CLMNAHTT | |
| SCHEMBL11074488 | 0.82 | PTGS2 (0.43) | HSD11B1CCR2MAOBMAOAMEN1 | |
| SCHEMBL11074486 | 0.82 | PTGS2 (0.43) | HSD11B1CCR2MAOBMAOAMEN1 | |
| SCHEMBL10532363 | 0.82 | ALDH1A1 (0.39) | MAOBALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL11078444 | 0.81 | GRIN2B (0.40) | HSD11B1ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11074556 | 0.81 | CCR2 (0.46) | CCR2ALDH1A1MEN1KMT2AADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4118417-A | Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1978-10-03 | — | — | US | claimed |
| US-20080009538-A1 | Methods and compositions for the treatment of urinary incontinence | DOV PHARMACEUTICAL, INC. | 2008-01-10 | — | — | US | disclosed |
| EP-1807071-A4 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV PHARMACEUTICAL INC (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1807071-A2 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV Pharmaceutical Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060100263-A1 | Antipyretic compositions and methods | DOV PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006050520-A2 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV PHARMACEUTICAL, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4196120-A | 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4118417-A | Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009538-A1 | Methods and compositions for the treatment of urinary incontinence | BPHL, MYOF, NISCH | HSD11B1 2176/4885CCR2 2013/4885NTRK3 1648/4885 |
| US-20060100263-A1 | Antipyretic compositions and methods | GABRE, HTR5A, TPH2 | HSD11B1 1485/4885CCR2 4078/4885NTRK3 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.